Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 3,430 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 3,430 shares of Natera stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $1,462,346.20. Following the completion of the transaction, the chief executive officer directly owned 91,232 shares in the company, valued at approximately $38,895,850.88. This represents a 3.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $919,184.00.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total value of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total value of $819,415.64.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $11.58 during mid-day trading on Thursday, hitting $436.00. 1,325,469 shares of the stock were exchanged, compared to its average volume of 1,585,948. The stock’s fifty day simple moving average is $375.27 and its two-hundred day simple moving average is $265.54. Natera, Inc. has a twelve month low of $181.00 and a twelve month high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter last year, the company posted ($0.74) EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

Hedge Funds Weigh In On Natera

A number of institutional investors have recently bought and sold shares of the business. Trust Co. of Vermont acquired a new position in Natera during the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC acquired a new position in shares of Natera during the second quarter worth $30,000. Continuum Advisory LLC acquired a new position in shares of Natera during the second quarter worth $33,000. International Assets Investment Management LLC lifted its stake in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Rakuten Securities Inc. bought a new position in shares of Natera in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on NTRA. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Natera in a report on Monday, July 6th. Guggenheim boosted their price target on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Rothschild & Co Redburn assumed coverage on shares of Natera in a research report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price objective for the company. UBS Group raised their price objective on Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $394.31.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.